NVUS - ト―カイ・ファ―マシュ―ティカルズ (Novus Therapeutics Inc.)

NVUSのニュース

   Novus Therapeutics Appoints June Lee, M.D., to Board of Directors  2020/12/09 13:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics announced the appointment of June Lee, M.D., to the company’s Board of Directors.
   Israel Gp Ltd. Orbimed Sells 103,200 Shares of Novus Therapeutics, Inc. (NASDAQ:NVUS) Stock  2020/12/06 09:46:49 Watchlist News
Novus Therapeutics, Inc. (NASDAQ:NVUS) major shareholder Israel Gp Ltd. Orbimed sold 103,200 shares of the company’s stock in a transaction dated Wednesday, December 2nd. The shares were sold at an average price of $21.60, for a total value of $2,229,120.00. The sale was disclosed in a filing with the SEC, which is available at this […]
   Zacks: Analysts Anticipate Novus Therapeutics, Inc. (NASDAQ:NVUS) to Post -$1.64 EPS  2020/11/16 17:23:30 Transcript Daily
Wall Street brokerages expect Novus Therapeutics, Inc. (NASDAQ:NVUS) to report earnings of ($1.64) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Novus Therapeutics’ earnings. Novus Therapeutics reported earnings of ($3.96) per share in the same quarter last year, which indicates a positive year over year growth rate of 58.6%. […]
   Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16  2020/11/10 22:04:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corpo
   Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis  2020/11/02 13:00:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics Announces First Patient Enrolled in Phase 2a Clinical Trial of Anti-CD40L Antibody AT-1501 in Amyotrophic Lateral Sclerosis
   Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media  2020/03/02 11:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics completes enrollment of phase 2a trial in patients with acute otitis media (C-006) and expects to report data by early June 2020.
   Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds  2020/01/10 22:19:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
   Novus Therapeutics Reports Third Quarter 2019 Financial Results  2019/11/13 12:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #earnings--Novus Therapeutics reports third quarter 2019 financial results, Phase 2a data expected in the first half 2020 & participation in investor conferences
   Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion  2019/10/29 11:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion
   The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch  2019/10/16 11:06:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Kodiak Sciences Inc (NASDAQ: KOD ) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) (announced positive results for a Phase 2 study of its drug to treat Friedreich ataxia) Relmada Therapeutics Inc (NASDAQ: RLMD ) ( announced positive Phase 2 results for drug to treat treatment-resistant depression) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 15) Auris Medical Holding Ltd (NASDAQ: EARS ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) Chimerix Inc (NASDAQ: CMRX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Heat Biologics Inc (NASDAQ: HTBX ) INmune Bio Inc (NASDAQ: INMB ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Novus Therapeutics Inc (NASDAQ: NVUS ) Orgenesis Inc (NASDAQ: ORGS ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precision BioSciences Inc (NASDAQ: DTIL ) Pulmatrix Inc (NASDAQ: PULM ) Sierra Oncology Inc (NASDAQ: SRRA ) Strongbridge Biopharma plc (NASDAQ: SBBP ) Stocks In Focus Akebia Sues CMS For Restoring Coverage For Kidney-Disease Related Anemia Drug Akebia Therapeutics Inc (NASDAQ: AKBA ) has filed a compliant in federal district court against the Centers of Medicare & Medicaid Service and the U.S.
   Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds  2020/01/10 22:19:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
   Novus Therapeutics Reports Third Quarter 2019 Financial Results  2019/11/13 12:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #earnings--Novus Therapeutics reports third quarter 2019 financial results, Phase 2a data expected in the first half 2020 & participation in investor conferences
   Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion  2019/10/29 11:30:00 Business Wire
IRVINE, Calif.--(BUSINESS WIRE)---- $NVUS #otitismedia--Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion
   The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch  2019/10/16 11:06:15 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Oct. 15) Celgene Corporation (NASDAQ: CELG ) Eagle Pharmaceuticals Inc (NASDAQ: EGRX ) Kodiak Sciences Inc (NASDAQ: KOD ) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) (announced positive results for a Phase 2 study of its drug to treat Friedreich ataxia) Relmada Therapeutics Inc (NASDAQ: RLMD ) ( announced positive Phase 2 results for drug to treat treatment-resistant depression) Zoetis Inc (NYSE: ZTS ) Down In The Dumps (Biotech stocks hitting 52-week lows on Oct. 15) Auris Medical Holding Ltd (NASDAQ: EARS ) BENITEC BIOPHAR/S ADR (NASDAQ: BNTC ) Chimerix Inc (NASDAQ: CMRX ) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Fulcrum Therapeutics Inc (NASDAQ: FULC ) Heat Biologics Inc (NASDAQ: HTBX ) INmune Bio Inc (NASDAQ: INMB ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Karuna Therapeutics Inc (NASDAQ: KRTX ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) Novus Therapeutics Inc (NASDAQ: NVUS ) Orgenesis Inc (NASDAQ: ORGS ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precision BioSciences Inc (NASDAQ: DTIL ) Pulmatrix Inc (NASDAQ: PULM ) Sierra Oncology Inc (NASDAQ: SRRA ) Strongbridge Biopharma plc (NASDAQ: SBBP ) Stocks In Focus Akebia Sues CMS For Restoring Coverage For Kidney-Disease Related Anemia Drug Akebia Therapeutics Inc (NASDAQ: AKBA ) has filed a compliant in federal district court against the Centers of Medicare & Medicaid Service and the U.S.
   The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout  2019/10/11 12:14:27 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 10.) The Medicines Company (NASDAQ: MDCO ) Ra Pharmaceuticals Inc (NASDAQ: RARX ) ( announced a deal to be bought by Belgium's UCB) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 10.) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Alkermes Plc (NASDAQ: ALKS ) Atreca Inc (NASDAQ: BCEL ) AzurRx BioPharma Inc (NASDAQ: AZRX ) (announced CEO departure) BioNano Genomics Inc (NASDAQ: BNGO ) BioTelemetry Inc (NASDAQ: BEAT ) Cellectis SA (NASDAQ: CLLS ) Cerus Corporation (NASDAQ: CERS ) Chimerix Inc (NASDAQ: CMRX ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Clovis Oncology Inc (NASDAQ: CLVS ) Cocrystal Pharma Inc (NASDAQ: COCP ) CymaBay Therapeutics Inc (NASDAQ: CBAY ) DelMar Pharmaceuticals Inc (NASDAQ: DMPI ) Dermira Inc (NASDAQ: DERM ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Enochian Biosciences Inc (NASDAQ: ENOB ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Genprex Inc (NASDAQ: GNPX ) Gossamer Bio Inc (NASDAQ: GOSS ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Homology Medicines Inc (NASDAQ: FIXX ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Jaguar Health Inc (NASDAQ: JAGX ) (announced plans to explore options to license Mytesi in China) Meridian Bioscience, Inc. (NASDAQ: VIVO ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) MOTIF BIO PLC/S ADR (: MTFB) Novus Therapeutics Inc (NASDAQ: NVUS ) Obalon Therapeutics Inc (NASDAQ: OBLN ) Onconova Therapeutics Inc (NASDAQ: ONTX ) Orgenesis Inc (NASDAQ: ORGS ) PAVmed Inc (NASDAQ: PAVM ) Precision BioSciences …

calendar